SCHEMBL6715744

SCHEMBL6715744

NC(=O)Cc1ccc(OCCCl)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.54
CA2 P00918 1/20 0.50
LMNA P02545 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
KDM4E B2RXH2 2/20 0.48
CYP1A2 P05177 2/20 0.48
ADRB2 P07550 1/20 0.48
ADRB1 P08588 1/20 0.48
CNR1 P21554 1/20 0.48
ADRA1D P25100 1/20 0.48
ADRA1A P35348 1/20 0.48
ADRA1B P35368 1/20 0.48
GLA P06280 1/20 0.48
CYP3A4 P08684 1/20 0.48
TSHR P16473 1/20 0.48
NFKB1 P19838 1/20 0.48
THPO P40225 1/20 0.48
BLM P54132 1/20 0.48
PMP22 Q01453 1/20 0.48
CYP2D6 P10635 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8475224 0.84 TBXAS1 (0.55) TBXAS1CA2LMNATDP1ADRB2
SCHEMBL7660622 0.84 PLA2G4B (0.55) TBXAS1CA2LMNAKDM4ECYP1A2
SCHEMBL14403148 0.82 TBXAS1 (0.54) TBXAS1CA2KDM4ECYP1A2CYP2D6
Hydrochloric Acid SCHEMBL8938138 0.82 TBXAS1 (0.54) TBXAS1CA2LMNATDP1ADRB2
SCHEMBL21700175 0.82 KDM4E (0.66) TBXAS1LMNAKDM4ECYP1A2CYP2D6
SCHEMBL8605820 0.82 TBXAS1 (0.54) TBXAS1CA2LMNATDP1KDM4E
SCHEMBL18798799 0.82 PARP10 (0.64) TBXAS1CA2
SCHEMBL29639820 0.82 LMNA (0.58) TBXAS1LMNAKDM4ECYP1A2CYP2D6
SCHEMBL22773365 0.82 POLB (0.54) LMNAKDM4ECYP1A2CYP2D6PDE4A
SCHEMBL22384505 0.81 TBXAS1 (0.52) TBXAS1CA2LMNATDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119874681-A Indole derivative, preparation method thereof and application of indole derivative in resisting liver cancer 中国人民解放军北部战区总医院 2025-04-25 CN disclosed
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 TBXAS1 2280/4885CA2 988/4885LMNA 3700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.